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Summary
Exercise tolerance is one of the major complaints
from patients with chronic obstructive pulmonary
disease (COPD) and has significant impact on per-
ceived quality of life. Although the etiology of dys-
pnea in COPD is multifactorial, dynamic hyperin-
flation during exercise is a major contributor. Al-
though FEV1 has served as an important diagnos-
tic tool, it does not correlate well with patient’s re-
sponse or exercise performance. The 6 minute
walk test is also problematic and has limited use
in assessing patient’s response to treatment since
the test does not involve a fixed exercise stimulus.
Inspired capacity, as a marker of dynamic hyperin-
flation, measured at various time points during
constant load exercise testing does  seem to cor-
relate well with exercise endurance time as well as
the patient’s level of dyspnea making it a valuable
tool to assess the response of various therapeutic
modalities used in COPD. In this review we look at
the impact of a broad range of therapies used in
COPD and their effects on exercise. Bronchodila-
tors, inhaled corticosteroids, oxygen, pulmonary
rehabilitation and lung volume reduction surgery
all reduce dynamic hyperinflation and improve im-
portant patient outcomes.   
KEY WORDS: COPD, cardiopulmonary exercise test-
ing, dynamic hyperinflation.
Introduction 
Chronic obstructive pulmonary disease (COPD) is a
common respiratory disorder which is characterized
by airflow limitation and
dysfunction of both large
and small airways. It is as-
sociated with destruction of
the lung parenchyma and
its vasculature in variable
combinations. 
Exercise limitation repre-
sents an important feature of
COPD which negatively impacts patients quality of
life. Alleviation of symptoms of dyspnea and leg dis-
comfort and improvement in activity level are impor-
tant therapeutic goals. Although historically, the forced
expiratory volume in 1 second (FEV1) has been used
as a marker of disease severity, it correlates poorly
with symptoms and function and does 
not necessarily change with treatment (1). The aim of
this paper is first to review the importance of assess-
ing exercise capacity in COPD and the physiological
impact of COPD on exertion as well as the variety of
exercise tests available to clinicians at this time.  Fi-
nally, we will review the literature on the impact of a
broad range of therapies commonly used in the treat-
ment of COPD on exercise parameters.  
Exercise limitation in COPD 
Exercise limitation occurs insidiously in patients with
COPD.  Detecting dyspnea is difficult because pa-
tients tend to modify their activities to avoid dyspnea
(2). Furthermore, patients with COPD typically present
when there has already been a significant decline in
FEV1 accompanied by some degree of hyperinflation
and exertional dyspnea. Even patients with mild
COPD have been found to have profound physiologi-
cal effects when the respiratory system is put under
stress by exercise (3). Exercise
intolerance in COPD is mul-
tifactorial and includes a re-
duced ventilatory capacity,
increased work of breath-
ing, skeletal muscle dys-
function due to decondition-
ing and possibly skeletal
muscle apoptosis due to
systemic inflammation, and
destruction of the pul-
monary capillary bed by
emphysema (2) (Figure 1).
Intolerable dyspnea and leg
fatigue are typically the most common exercise limit-
ing symptoms (4). 
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During exercise in normal subjects, end expiratory
lung volume (EELV) remains stable or decreases as
exercise increases. The end inspiratory volume (EILV)
increases and tidal volume increases substantially.
This is in contrast to patients with COPD where, as
ventilatory demands increase in the setting of expira-
tory flow limitation, there is progressive air trapping
and further dynamic hyperinflation (DH) above already
increased resting values as depicted in Figure 2.
EELV increases and as exercise continues there is
progressively less inspiratory capacity (IC) available
as EELV increases toward total lung capacity (TLC).
The increase in EELV places the respiratory muscles
at a mechanical disadvantage since the elastic work of
breathing is increased owing to higher lung volumes
and the need to counteract the greater inward recoil of
the chest wall leading to the uncomfortable sensation
of dyspnea (2). Abnormal dynamic ventilatory me-
chanics and excessive chemostimulation during exer-
cise results in a widening disparity between escalating
central neural drive and restricted thoracic volume dis-
placement (5). This has been termed neuromechani-
cal uncoupling which is thought to form the basis for
the distressing sensation of an unsatisfied inspiration
as often occurs in COPD (5).
Measurement of symptoms, operational lung vol-
umes, spirometry and endurance during exercise
in patients with COPD
There is increasing evidence that the IC during exer-
cise, and the rate of change in IC during exercise (dy-
namic hyperinflation) are strong predictors of exertion-
al dyspnea intensity and exercise intolerance; both of
which are important patient-centered outcomes (6).
The extent of dynamic hyperinflation during exercise
varies inversely with the level of resting hyperinflation.
Also, for a given degree of airflow obstruction, patients
with lower diffusion capacity appear to have faster
rates of dynamic hyperinflation (7). Although the FEV1
is used in the diagnosis and physiological staging of
COPD; it has limited application in assessing the re-
sponse to bronchodilators or predicting patient-cen-
tered outcomes in terms of exercise ability or dyspnea
(2). Data from the National Emphysema Treatment
Trial (NETT) demonstrated that for any FEV1, there
was a wide range of maximum exercise capacity ob-
served illustrating the limited predictive value of FEV1
for exercise capacity in individual patients (8).
In COPD, the best physiological correlate of peak oxy-
gen uptake (Vo2) is the peak tidal volume which in turn
is determined primarily by the peak IC during exercise
or the resting IC (7). Exer-
tional dyspnea also corre-
lates best with constraints
on tidal volume. There is a
clear statistical association
between the level of resting
and dynamic hyperinflation,
the degree of tidal volume
restriction during exercise,
and peak exercise perform-
ance (7). When the tidal
volume during exercise ap-
proximates the peak IC, fur-
ther volume expansion is nearly impossible despite
further increase in inspiratory muscle effort. In a mul-
Cardiopulmonary exercise testing in COPD
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There is a clear stati-
stical association
between the level of
resting and dynamic
hyperinflation, the
degree of the tidal vo-
lume restriction du-
ring exercise, and
peak exercise perfor-
mance.
Figure 1 - Central role of air trapping and hyperinflation in the pathophysiology of chronic obstructive pulmonary disease
(COPD). Although related to increased airways resistance, hyperinflation correlates more directly with patient-centered out-
comes. Activity limitation leads to deconditioning, which, in turn, increases ventilator requirements, establishing a cycle of
decline leading to worsening hyperinflation. Anxiety and hypoxemia cause tachypnea, which worsens hyperinflation by al-
lowing less time for exhalation [Reprinted with permission from Am J Med (2)].
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tiple regression analysis with symptom limited peak
Vo2 as the dependent variable and several relevant
physiological measurements as independent vari-
ables, including FEV1 and FEV1/FVC ratio, peak tidal
volume (VT) emerged as the strongest contributory
variable explaining 47% of the variance in exercise
limitation which in turn correlated strongly with resting
and peak dynamic IC. Volume constraints contributed
disproportionately to both exercise intolerance and
dyspnea in patients with COPD (7). 
Using a randomized, double blind, two-period cros -
sover design allowing patients to serve as their own
control, O’Donnell et al. examined the reliability and
reproducibility of a variety of cardiopulmonary respon -
ses during exercise testing to determine whether they
can accurately predict symptomatic response (6). Re-
liability (or reproducibility) was established by analyz-
ing baseline measurements taken at repeated visits in
29 patients with moderate to severe COPD. Respon-
siveness to treatment was assessed by comparing the
acute effects of two treatments (single dose nebulized
ipratropium bromide versus placebo over a three
week period followed by crossing over to the alternate
treatment for an additional 3 week period after a 2 to
7 day washout period). Exercise performance during
constant load testing was assessed by looking at
symptom-limited peak endurance time, peak oxygen
uptake (Vo2) and peak minute ventilation (VE). Al-
though each measurement showed excellent repro-
ducibility; only exercise endurance time was both reli-
able and responsive to change. Serial IC measure-
ments during exercise were reproducible and respon-
sive, and changes in IC after
bronchodilator therapy cor-
related best with changes
in exertional dyspnea com-
pared to any other resting
or exercise parameter in-
cluding FEV1 and FVC. An
increase in IC (or reduction
in dynamic hyperinflation)
of about 0.3-0.4L during
exercise translated into a
clinically significant im-
provement in exercise en-
durance and reduction in exertional dyspnea (6).
Exercise testing in COPD
The six minute walk test (6MWT) is frequently used to
assess the functional status of patients with COPD.
S. L. Corriveau  et al.
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Figure 2 - Operational lung volumes at rest and with exercise in healthy subjects and in patients with chronic obstructive pul-
monary disease (COPD). On the compliance curve of healthy subjects, the small ellipse (A) represents the volume at rest,
and the large ellipse (B) represents the volume during exercise. Similarly, on the compliance curve of patients with COPD,
the small ellipse on the upper curve represents the volume at rest, while the large ellipse (C) on the upper curve represents
the volume during exercise. The 2 ellipses on the lower curve represent the volume at rest and during exercise in healthy
subjects for comparison. For the patients with COPD, the increase in end-expiratory lung volume (EELV) during exercise rep-
resents dynamic hyperinflation. The hypothetical “dyspnea threshold” and “dyspnea limit” are also shown. EILV= end-inspi-
ratory lung volume; RV= residual volume; TLC= total lung capacity [Reprinted with permission from Am J Med (2)].
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The test is reliable, valid,
safe, and inexpensive (9).
It is easy to perform and re-
quires minimal equipment.
It reflects the capacity to
undertake day to day activ-
ities and is typically carried
out in a 50m long corridor
and observed by trained
staff. The threshold at
which a difference in the
6MWT was associated with
a small but noticeable dif-
ference in perceived walking ability for patients with
COPD is 54m (CI 37 to 71m) (9). As occurs during car-
diopulmonary exercise testing (CPET), dynamic hy-
perinflation determined by measuring IC occurs in
6MWT (10). The 6MWT is problematic to assess treat-
ment outcomes because the test does not involve a
fixed exercise stimulus even when repeated in the
same patient (2). It also does not allow the routine
measurements of more detailed ventilator responses
such as IC, tidal volume and VO2 and VCO2 during ex-
ercise.
An endurance test performed at a submaximal con-
stant work rate does offer the advantage of a fixed ex-
ercise stimulus (2). Both incremental testing and con-
stant load endurance testing have been used to as-
sess therapeutic responses in patients with COPD.
Whereas incremental testing generally begins with 3
min of rest followed by 3 min of unloaded pedalling
then an incremental phase of 5-25W/min until the pa-
tient reaches exhaustion; constant load endurance
testing is similar but the work rate is adjusted to 75%
of Wmax (highest work rate subject could maintain for
≥30 s) (11). Increasingly, investigators are using con-
stant load endurance testing at a standardized sub-
maximal work load to evaluate the impact of interven-
tions because it is highly sensitive in measuring acute
changes in exercise endurance following various ther-
apies and is more sensitive than other exercise
modalities including 6MWT (12). The downside is that
you require an initial incremental test to establish the
Wmax, however subsequently the endurance test is
more responsive to change.
The exercise endurance time is a sensitive measure
and is used as an outcome measure when assessing
various treatment modalities. It refers to the duration
of loaded pedaling from the commencement of pedal-
ing to the symptom limited endpoint where the patient
indicates they need to stop or when they can no
longer maintain the required pedaling rate (13). The
minimum clinically relevant improvement (MCID) in
endurance time was previously reported by Puente-
Maestu et al. to be  ̴101 seconds (14). Improved exer-
cise performance should be reflected in a prolonged
endurance time for exactly the same stimulus after in-
tervention. Many physiological measures including
dyspnea ratings, spirometry and measurement of IC
can be compared at isotome, which is a standardized
time near the end of exercise that can be used for
comparison between treatment groups.
Therapies used in COPD and their effect on exer-
cise
Bronchodilators 
In clinical practice, bronchodilators are recommended
for symptomatic relief in COPD patients with all stages
of severity. Various Authors have examined the rela-
tionships between lung hyperinflation, respiratory dis-
comfort and exercise intolerance in patients with
COPD following treatment with bronchodilators which
include both beta agonist and anticholinergic medica-
tions. 
Belman et al. assessed the effects of bronchodilator
induced changes on dynamic lung volumes in 13 pa-
tients with moderate to severe COPD in a blinded,
randomized, cross-over study. Using incremental ex-
ercise testing, patients received 3 puffs of placebo or
3 puffs of albuterol, a short acting beta agonist, via
MDI and then on subsequent
visits received the alternate
therapy. Following treat-
ment with albuterol, Borg
dyspnea rating scale im-
proved by 1.4 units, which
exceeds the MCID of 1 unit.
Although FEV1 and FVC
tended to improve following
bronchodilatation; neither
was associated with im-
provement in breathless-
ness. Instead, the best predic-
tor of breathlessness was a reduction in dynamic hy-
perinflation (1). These findings were similar to another
study examining the effects of salmeterol, a long act-
ing beta agonist, versus placebo in 23 patients with
moderate to severe COPD using constant load exer-
cise testing (15). In this study, salmeterol resulted in
improved lung function and increased expiratory flow
rates. EELV reduced by about 0.32L with an associat-
ed increase in IC by 0.33L. The greater IC led to im-
proved tidal volume in the salmeterol group. Symptom
limited exercise endurance time improved by 1.6min
following treatment with salmeterol. Exertional dysp-
nea also tended to improve in the salmeterol group
and correlated best with increased tidal volume, dy-
namic IC as well and resting IC (15).
Tiotropium is a long acting anticholinergic which has
been shown to achieve sustained bronchodilatation
and to improve quality of life in patients with COPD. It
was studied by O’Donnell et al. in a multicentre dou-
ble blind placebo controlled trial to evaluate its effects
on exercise endurance (12). 187 patients with stable
moderate-severe COPD were randomized to receive
tiotropium 18mcg daily versus placebo. Exercise en-
durance time increased significantly from baseline in
the treatment group after the first dose with further in-
creases after 21 days and 42 days of treatment. There
was a mean difference in endurance time of 67s be-
tween tiotropium and placebo after 21 days of treat-
ment and 105s after 42 days of treatment. Those in
the tiotropium group were also able to exercise longer
Cardiopulmonary exercise testing in COPD
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rement of IC can be
compared at isoto-
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likely as a result of in-
creased tidal expira-
tory flow rates and
lung emptying due to
enhanced airway pa-
tency following bron-
chodilator therapy.
SOB n.3-15 3 bozza_-  06/02/16  19:33  Pagina 91
© 
CI
C
Ed
izio
ni 
Int
e n
az
ion
ali
before reaching the same degree of dyspnea. These
findings were sustained over a 6 week period. Operat-
ing lung volumes at rest and throughout exercise were
decreased. A correlation analysis showed close inter-
relationships between improved IC, reduced exertion-
al dyspnea and improved endurance time during treat-
ment with tiotropium. Although, tiotropium also result-
ed in consistent improvements in FEV1 compared to
placebo, as in previous studies, this did not correlate
with dyspnea ratings or exercise endurance time (12).  
Indacaterol, a novel ultra-long acting B2 agonist pro-
viding 24hr bronchodilatation was compared to place-
bo in patients with moderate-severe COPD. After 3
weeks of treatment, patients in the treatment group
had an increased exercise endurance time of 111s
(16). These findings were particularly apparent in pa-
tients with more severe COPD (FEV1<50% predicted)
where the exercise time was 229s higher in the treat-
ment group. The end exercise IC was significantly
higher with indacaterol than with placebo both on day
1 and after 3 weeks of therapy with differences of 190
mL and 280 mL respectively. Although there was no
significant difference between treatment groups in
Borg dyspnea scores at the end of exercise, patients
were able to endure constant work rate for longer be-
fore experiencing equivalent levels of dyspnea. 
These are but a few studies which provide further sup-
port that exercise performance in COPD patients with
and without bronchodilator therapy is determined in
part by the degree of lung hyperinflation and the asso-
ciated mechanical restriction at rest. The increased IC
at rest and during exercise likely occurs as a result of
increased tidal expiratory flow rates and lung empty-
ing due to enhanced airway patency following bron-
chodilator therapy (12).
Inhaled corticosteroids 
It is recommended that patients with moderate-severe
COPD who are prone to exacerbations be treated with
an inhaled corticosteroid (ICS) in combination with a
long acting bronchodilator (17). ICS monotherapy is
typically avoided given its association with pneumonia
(18). Guenette et al. assessed whether the addition of
fluticasone propionate 500ug  twice daily in patients
with moderate to severe COPD led to an improvement
in dyspnea and exercise endurance time using a con-
stant load cycle protocol. Seventeen subjects were
enrolled in the study; all of whom were on baseline in-
haled long-acting bronchodilators. Following 2 weeks
of treatment with fluticasone propionate, exercise en-
durance time improved by an average of 188s when
compared to placebo exceeding the current MCID of
100s. This however was associated with an improve-
ment in standardized dyspnea ratings in only 10 of the
17 patients under study. There was variability among
subjects in their response to treatment. Specifically, 2
subjects had unusual increases in endurance time
whereas one had an unusual reduction in endurance
time. Removal of these three outliers reduced the ob-
served improvement in exercise endurance time to
152s however improved statistical significance. Oper-
ating lung volumes were consistently reduced at rest
and throughout exercise in the fluticasone group. Al-
though the residual volume (RV), total lung capacity
(TLC) and functional residual capacity (FRC) were re-
duced by about 0.3L there was no reciprocal increase
in vital capacity (VC) and inspiratory capacity (IC). In-
stead there was a net reduction in TLC and an im-
provement in FEV1/FVC ratio. This is in contrast to re-
sults of previous studies looking at the effects of bron-
chodilators where the ratio is unchanged but the IC
improves. Also in this study, FEV1 improved by 115 ml
following 2 weeks of fluticasone which is large and out
of keeping with results from other similar studies.
Nonetheless, spirometric improvements were not as-
sociated with increases in endurance time (16). Im-
provements in exercise endurance, although statisti-
cally significant were highly variable and the mecha-
nism by which this occurs with inhaled corticosteroids
is unclear.  
Phosphodiesterase inhibitors
Roflumilast, a phosphodiesterase-4 inhibitor should
be considered for patients with moderate to severe
COPD with chronic bronchitis and a history of at least
one exacerbation in the previous year to prevent acute
exacerbations of COPD (17). Roflumilast seems to
work as an anti-inflammatory agent and has no direct
effects on airway smooth muscle (19). In a 12 week
study conducted by O’Donnell et al. to assess the ef-
fects of roflumilast in patients with COPD and under-
lying lung hyperinflation; patients treated with roflumi-
last had no significant change in static lung hyperinfla-
tion, exercise endurance time or dyspnea ratings. Rof-
lumilast however did seem to prevent worsening dy-
namic lung hyperinflation during exercise as occurred
in those randomised to placebo. FEV1 did improve by
an average of 84mL in the roflumilast group however
this did not translate into improved exercise tolerance
or dyspnea rating. Given the lack of improvement in IC
(or decrease in dynamic hyperinflation), it is not sur-
prising that endurance time was not increased when
compared to placebo (19).
Oxygen
O’Donnell et al.  studied 11 clinically stable hypoxemic
patients with advanced COPD comparing the acute ef-
fects of room air and 60% oxygen on various parame-
ters during constant load exercise testing (10). Oxy-
gen improved both dyspnea and exercise tolerance in
these patients. Endurance time increased significantly
by an average of 4.7 minutes. Borg-time ratings of
both dyspnea and leg discomfort fell significantly in
those receiving oxygen. There was a modest reduc-
tion in ventilation by about 3L/min achieved by a re-
duction in breathing frequency. Hyperoxia also result-
ed in a delay in dynamic hyperinflation during exercise
and a reduction in operational lung volumes of about
S. L. Corriveau  et al.
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0.3L which resulted in improvement in important pa-
tient-centered outcomes (10).   
A similar study was conducted by Somfay et al. how-
ever subjects consisted of ten clinically stable patients
with COPD who were not hypoxemic (oxygen satura-
tion >92% at rest and >88% during exercise) (20).
During five subsequent constant work rate tests, sub-
jects breathed compressed air, 30%, 50%, 75% or
100% oxygen in a random
and blinded fashion. Similar
to previous studies, during
normoxic exercise EELV in-
creased considerably in pa-
tients with COPD compared
to normal subjects. Howev-
er, increasing fractional in-
spired oxygen in a dose de-
pendent manner up to 50%
resulted in attenuation of
dynamic hyperinflation, de-
creased minute ventilation
and respiratory frequency
which translated into an im-
provement in exercise en-
durance time in patients
with COPD. Reduced dysp-
nea ratings and operational lung volumes accompa-
nied this improvement. Increasing Fi02 to 0.3 pro-
duced the most substantial changes in exercise toler-
ance, the sensation of dyspnea and the physiologic
responses to exercise whereas increasing further to
an oxygen concentration of 50% produced an addi-
tional but smaller change. Increasing the concentra-
tion of oxygen above 50% had no further impact on
exercise endurance or breathlessness (20). Although
changes in operating lung volumes could account for
a portion of variance in exercise tolerance or dyspnea;
there are likely other contributing factors such as im-
proved muscle function.
Although these and other similar studies provide evi-
dence that supplemental oxygen compared to placebo
increases exercise capacity in patients performing sin-
gle-assessment exercise tests; there is little support
for oxygen supplementation for exercise training in
nonhypoxemic patients with COPD (21). There is also
the real concern that uncontrolled oxygen may lead to
hypercapnia in patients with COPD through worsening
ventilation-perfusion mismatch, Haldane effect and
hypoventilation (22). The first study demonstrated an
increase in arterial PCO2 on 60% oxygen (53.3 vs
57.6 p<0.1), which is especially significant given the
short duration of treatment (22). 
Lung volume reduction surgery
Several clinical trials have examined the benefits of
lung-volume reduction surgery (LVRS) in selected pa-
tients with upper-lobe predominant emphysema and
hyperinflation. Overall, LVRS results in improved stat-
ic pulmonary function, improved functional status and
decreased breathlessness and reduced dynamic hy-
Cardiopulmonary exercise testing in COPD
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perinflation (23, 24). Exercise testing protocols did dif-
fer between studies and did not involve the more com-
monly used constant load exercise test but rather in-
cremental exercise test or 6MWT to assess exercise
endurance. Although one trial was identified that used
CWR exercise testing, dynamic hyperinflation as ex-
pressed by IC was not measured until partway
through the trial preventing sufficient power to reach
statistical significance (24).
Pulmonary rehabilitation 
Pulmonary rehabilitation
has also been shown to im-
prove exercise tolerance in
patients with COPD by re-
ducing the degree of hy-
perinflation at a given level
of exercise. During CWR
exercise, ventilation and
breathing rate were lower
after training. There was al-
so a reduction in hyperinfla-
tion as reflected by a higher IC. The improvement in
exercise tolerance correlated with the change in iso-
time IC suggesting that exercise training decreases
ventilatory requirements and dynamic hyperinflation
(25).
Conclusion
Exercise limitation is common in patients with COPD
and is associated with a decreased quality of life.
Among the multitude of symptoms faced by those with
this disease, dyspnea is one of the most distressing
with a great impact on quality of life and manifests as
exercise intolerance. Although exercise intolerance is
multifactorial, it appears to be tightly linked to volume
constraints and the extent of dynamic hyperinflation
that typically occurs in patients with COPD during ex-
ercise. Inspiratory capacity measured at rest, at a
standardized level of submaximal exercise, and at
peak exercise is highly reproducible and responsive to
change (6). When compared to other physiological pa-
rameters measured during exercise, an increase in IC
(or reduction in dynamic hyperinflation) of approxi-
mately 0.3 to 0.4L during exercise translates into a
clinically significant improvement in exercise en-
durance and reduction in exertional dyspnea. Given
its reliability and responsiveness to therapy it is used
to assess the effects of novel therapies in COPD. It al-
so gives a more comprehensive physiological assess-
ment of the patient than other tests such as spirome-
try or the 6MWT. We have reviewed here a number of
the commonly used treatments in COPD and their
physiological effects as evaluated by cardiopulmonary
exercise testing. These studies help to illustrate the
pathophysiology of dyspnea in COPD and the mecha-
nisms of dyspnea relief in those treatments with
proven benefit to exercise capacity.
Increasing FiO2 to 0.3
in  hypoxemic COPD
patients produced the
most  substant ia l
changes in exercise
tolerance, the sensa-
tion of dyspnea and
the physiologic re-
sponses to exercise.
Increasing further
produced smaller
changes, but there is
the real concern that
may lead to hypercap-
nia in patients with
COPD.
The improvement in
exercise tolerance
correlated with the
change in isotime IC
suggesting that exer-
cise training decrea-
ses ventilatory requi-
rements and dyna-
mic hyperinflation.
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